Opinion
Video
An Overview of the ARANOTE Trial
Author(s):
A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.
Video Player is loading.
Advanced Prostate Cancer Treatment Strategies
Panel Introduction
Featured Expert:
- Neal D. Shore, MD, FACS: Medical oncologist and urologist at Carolina Urologic Research Center, Myrtle Beach, South Carolina. Dr Shore is a recognized researcher in urologic oncology with expertise in clinical trials for advanced prostate cancer treatments.
Expert Specialty Areas
- Urologic oncology
- Clinical research in metastatic hormone-sensitive prostate cancer (mHSPC)
- Novel androgen receptor pathway inhibitors
- Prostate-specific antigen response as predictive biomarker
ARANOTE Trial Overview
Key Themes:
- Phase 3 clinical trial evaluating darolutamide plus ADT in patients with mHSPC
- Trial design and methodology
- Significant efficacy outcomes
Expert Insights:
- Dr Shore provided an overview of the ARANOTE trial design, which evaluated darolutamide in combination with androgen deprivation therapy (ADT) for patients with mHSPC.
- The discussion highlighted the topline results demonstrating clinical benefit with this treatment approach.
Related Videos
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Treatment or Lack of Treatment of Small Renal Masses
The current treatment landscape of mHSPC
Strengths and Weaknesses of Imaging Modalities in ccRCC
BPH: Strategies for Guiding Patients From Medication to Intervention
Representation of Black men with mHSPC in clinical trials
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Non–Muscle Invasive-Bladder Cancer Overview
Related Content
